Yeong Chai-Hong, Cheng Mu-hua, Ng Kwan-Hoong
Department of Biomedical Imaging & University of Malaya Research Imaging Centre, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; Department of Nuclear Medicine, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, China.
J Zhejiang Univ Sci B. 2014 Oct;15(10):845-63. doi: 10.1631/jzus.B1400131.
The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131 ((131)I), phosphorous-32 ((32)P), strontium-90 ((90)Sr), and yttrium-90 ((90)Y), have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel developments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.
放射性核素在治疗中的潜在应用已被认识数十年。许多放射性核素，如碘-131（¹³¹I）、磷-32（³²P）、锶-90（⁹⁰Sr）和钇-90（⁹⁰Y），已成功用于治疗多种良性和恶性疾病。最近，由于引入了多种用于治疗转移性骨痛、神经内分泌及其他恶性或非恶性肿瘤的新型放射性核素和放射性药物，核医学的这一分支迅速发展。如今，放射性核素治疗领域正处于令人兴奋的阶段，未来几年有望实现更大的增长和发展。例如，在亚洲，甲状腺和肝脏疾病的高发病率促使人们开展了许多使用靶向放射性核素治疗的新进展和临床试验。本文综述了常用治疗性放射性核素的特性和临床应用，以及将新型放射性核素转化为临床治疗方法所涉及的问题。
